Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06313437 · ClinicalTrials.gov registry record · Phase 1

Revumenib in Combination With 7+3 + Midostaurin in AML

A Phase 1 study of Acute Myeloid Leukemia and Leukemia, sponsored by Richard Stone, MD.

Recruiting
Registry status
Phase 1
Development phase
22
Enrollment target
2
Study locations

NCT06313437 is a Phase 1 study of Acute Myeloid Leukemia and Leukemia that is actively recruiting participants, run by Richard Stone, MD. The registered enrollment target is 22 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06313437, a Phase 1 study of Acute Myeloid Leukemia and Leukemia, is actively recruiting participants, sponsored by Richard Stone, MD.

RECRUITING
Registry status
Phase 1
Development phase
22 participants
Enrollment target
2
Study locations

Study Summary

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). The names of the study drugs involved in this study are: * Revumenib (SNDX-5613) (a type of menin inhibitor) * Midostaurin (a type of multi-kinase including FLT3 inhibitor) * Cytarabine (a type of antineoplastic agent) * Daunorubicin (a type of antineoplastic agent)

Conditions Studied

Acute Myeloid Leukemia Leukemia AML AML, Adult AML With Gene Mutations

Interventions

  • DRUG Cytarabine
  • DRUG Daunorubicin
  • DRUG Revumenib
  • DRUG Midostaurin

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2024-12-06
Est. Completion 2027-03-02
Phase Phase 1

Sponsor

Richard Stone, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06313437

The ClinicalTrials.gov registry entry for NCT06313437 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (81% lower). The listed sponsor is Richard Stone, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Cytarabine is the first listed.

NCT06313437 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06313437 about?

NCT06313437 is a clinical study titled "Revumenib in Combination With 7+3 + Midostaurin in AML". This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostauri...

What is the current status of trial NCT06313437?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2024-12-06. Estimated completion is 2027-03-02.

What conditions does trial NCT06313437 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Leukemia, AML, AML, Adult, AML With Gene Mutations.

What interventions are being tested in trial NCT06313437?

The interventions under investigation include: Cytarabine (DRUG), Daunorubicin (DRUG), Revumenib (DRUG), Midostaurin (DRUG).

Who is sponsoring clinical trial NCT06313437?

This trial is sponsored by Richard Stone, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06313437 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Leukemia

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.